Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tmunity Raises $100m Series A To Fund Next-Gen T-Cell Therapy Trials

Executive Summary

Tmunity launched in early 2016 with $10m in seed funding for novel T-cell therapies, two of which are now in the clinic. The company reunites former Novartis cell therapy head Oz Azam and CAR-T researchers from the University of Pennsylvania.

Advertisement

Related Content

Group Working To Close 'Standards Gaps' For Cell And Gene Therapies
Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy
Novartis Cell Therapy Unit To Close: Implications For CAR-T Could Be Big
VC Round-Up: Microbiome Focused Lodo, T-Cell Firm Tmunity, And More
Companies Clearing Cell And Gene Therapy Manufacturing Hurdles
A New Industry-Academic Model: Novartis And Penn Make A Splash In Cancer Immunotherapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100257

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel